Display Settings:

Format
Sort by

Send to:

Choose Destination

    Results: 5

    1.

    Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.

    L'homme RF, Nijland HM, Gras L, Aarnoutse RE, van Crevel R, Boeree M, Brinkman K, Prins JM, Juttmann JR, Burger DM.

    AIDS. 2009 Apr 27;23(7):863-5.PMID: 19352137 [PubMed - indexed for MEDLINE]Related articles

    2.

    High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets.

    Nijland HM, L'homme RF, Rongen GA, van Uden P, van Crevel R, Boeree MJ, Aarnoutse RE, Koopmans PP, Burger DM.

    AIDS. 2008 May 11;22(8):931-5.PMID: 18453852 [PubMed - indexed for MEDLINE]Related articles

    3.

    Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.

    Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE.

    Antimicrob Agents Chemother. 2007 Jul;51(7):2546-51. Epub 2007 Apr 23.PMID: 17452486 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes.

    Nijland HM, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RH, van der Ven AJ, Danusantoso H, Aarnoutse RE, van Crevel R.

    Clin Infect Dis. 2006 Oct 1;43(7):848-54. Epub 2006 Aug 22.PMID: 16941365 [PubMed - indexed for MEDLINE]Related articles

    5.

    Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis.

    Ruslami R, Nijland H, Aarnoutse R, Alisjahbana B, Soeroto AY, Ewalds S, van Crevel R.

    Antimicrob Agents Chemother. 2006 Feb;50(2):822-3. No abstract available. PMID: 16436757 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Find related data

    Search details

    » See more...